Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cefepime/taniborbactam - VenatoRx Pharmaceuticals

Next Previous
Drug Profile

Cefepime/taniborbactam - VenatoRx Pharmaceuticals

Alternative Names: Cefepime/VNRX-5133; VNRX-5133/VNRX-5022; VNRX5133/Cefepime

Latest Information Update: 04 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator VenatoRx Pharmaceuticals
  • Developer Global Antibiotic Research and Development Partnership; VenatoRx Pharmaceuticals
  • Class Anti-inflammatories; Antibacterials; Beta-lactams; Cephalosporins; Small molecules; Urinary anti-infective agents
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Pyelonephritis; Urinary tract infections
  • Preclinical Nosocomial pneumonia

Most Recent Events

  • 25 Mar 2025 Venatorx Pharmaceuticals withdraws the phase III CERTAIN-2 trial in Nosocomial-pneumonia and Ventilator-associated-pneumonia (IV), as study suspended prior to enrolment (NCT06168734)
  • 16 Oct 2024 Pharmacodynamics data from preclinical studies in Bacterial infections presented at IDWeek 2024 (IDW-2024)
  • 28 Aug 2024 Everest Medicines announces intention to submit NDA to NMPA for Urinary tract infections (Complicated) in mainland China, in 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top